• Publications
  • Influence
How I treat the acquired von Willebrand syndrome.
The acquired von Willebrand syndrome (AVWS) is a bleeding disorder that is frequently unrecognized or is misdiagnosed as von Willebrand disease. AVWS is characterized by structural or functionalExpand
  • 190
  • 16
  • PDF
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single‐centre cohort study
Summary.  Background: Diagnosis of acquired von Willebrand syndrome (AVWS) remains challenging. Diagnostic algorithms suggest the use of factor VIII (FVIII:C), von Willebrand factor antigen (VWF:Ag),Expand
  • 121
  • 8
Compensatory visual field training for patients with hemianopia after stroke
Twenty-one patients with hemianopia received 4 weeks of compensatory visual field training. Detection of and reaction time to visual stimuli were measured with eyes fixating (condition A) and withExpand
  • 126
  • 8
  • PDF
Acquired hemophilia A: Updated review of evidence and treatment guidance
Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies (inhibitors) against endogenous factor VIII (FVIII) that leads to bleeding, which is often spontaneous and severe. AHAExpand
  • 101
  • 7
Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A
N8‐GP is a recombinant factor VIII (FVIII) with a site‐directed glycoPEGylation for the purpose of half‐life prolongation.
  • 121
  • 5
Biosynthesis of Glycosylphosphatidylinositols in Mammals and Unicellular Microbes
Abstract Membrane anchoring of cell surface proteins via glycosylphosphatidylinositol (GPI) occurs in all eukaryotic organisms. In addition, GPI-related glycophospholipids are important constituentsExpand
  • 110
  • 5
Diagnosis and treatment of acquired von Willebrand syndrome.
  • A. Tiede
  • Medicine
  • Thrombosis research
  • 1 December 2012
Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder that is characterized by structural or functional alterations in von Willebrand factor (VWF) caused by a range ofExpand
  • 55
  • 5
Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of bleeding episodes in patients with severe haemophilia A. ThisExpand
  • 68
  • 5
Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update.
Acquired von Willebrand syndrome (AVWS) is an acquired bleeding disorder, first reported in 1968, with clinical and laboratory features similar to inherited von Willebrand disease. This rare bleedingExpand
  • 75
  • 4
Bioequivalence between two serum‐free recombinant factor VIII preparations (N8 and ADVATE®) – an open‐label, sequential dosing pharmacokinetic study in patients with severe haemophilia A
Summary.  Recombinant coagulation factor VIII (rFVIII) concentrates provide a safe and efficacious replacement therapy for treatment and prevention of bleeding in patients with severe haemophilia A.Expand
  • 44
  • 4